Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Clinical Trial Evaluating Efficacy of Romiplostim Added to Standard of Care for Children and Young Adults With Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

NCT07001254 is registered in ClinicalTrials.gov with Anjali Sharathkumar as lead sponsor.

NCT NCT07001254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07001254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Clinical Trial Evaluating Efficacy of Romiplostim Added to Standard of Care for Children and Young Adults With Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
Lead sponsor
Anjali Sharathkumar
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 31, 2031
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aplastic anemia